Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth
Update your Virtual Booth on PharmaCompass, ask us 
About
International Sweetene...International Sweetener Colloquium
Not Confirmed
Not Confirmed
22-25 February, 2026
Not Confirmed
Not Confirmed
23-25 February, 2026
Clinical Trial Supply ...Clinical Trial Supply Europe
Not Confirmed
Not Confirmed
24-25 February, 2026
List your booth number for exhibitions, ask us 
CONTACT DETAILS
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Events
Webinars & Exhibitions
International Sweetener Colloquium
Not Confirmed
Contact SupplierInternational Sweetener Colloquium
International Sweetene...International Sweetener Colloquium
Industry Trade Show
Not Confirmed
22-25 February, 2026
Industry Trade Show
Not Confirmed
23-25 February, 2026
Clinical Trial Supply ...Clinical Trial Supply Europe
Industry Trade Show
Not Confirmed
24-25 February, 2026
Digital content
NEWS #PharmaBuzz
17 Feb 2026
// BUSINESSWIRE
https://www.businesswire.com/news/home/20260217311861/en/ViiV-Healthcare-showcases-long-acting-HIV-innovation-and-potential-of-ultra-long-acting-pipeline-including-new-data-for-first-third-generation-integrase-inhibitor-at-CROI-2026
19 Jan 2026
// REUTERS
https://www.reuters.com/business/healthcare-pharmaceuticals/japans-shionogi-boosts-viiv-stake-217-pfizer-exits-2026-01-20/
25 Nov 2025
// BUSINESSWIRE
https://www.businesswire.com/news/home/20251125605815/en/CAN-Community-Health-Presents-World-AIDS-Day-Concert-Featuring-Broadway-Legends-Adam-Pascal-Anthony-Rapp
28 Oct 2025
// PHARMIWEB
https://www.pharmiweb.com/press-release/2025-10-28/viiv-healthcare-launches-risk-to-reasons-initiative-in-the-uk-to-empower-women-to-take-control-of-their-hiv-prevention-choices
21 Oct 2025
// PHARMIWEB
https://www.pharmiweb.com/press-release/2025-10-21/global-fund-welcomes-renewed-commitment-from-gsk-and-viiv-healthcare-to-expand-community-led-health-solutions-with-6-million-joint-pledge-ahead-of-8t
17 Oct 2025
// BUSINESSWIRE
https://www.businesswire.com/news/home/20251015024690/en/ViiV-Healthcare-announces-96-week-data-reaffirming-Dovato-is-as-effective-as-Biktarvy-in-maintaining-virological-suppression-of-HIV-1-with-significantly-less-weight-gain
Drugs in Development
Details:
Fostemsavir is a small molecule drug, which is currently being evaluated in Phase III clinical studies for the treatment of hiv infections.
Lead Product(s): Fostemsavir,Dolutegravir Sodium,Lamivudine
Therapeutic Area: Infections and Infectious Diseases Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable February 06, 2026
Lead Product(s) : Fostemsavir,Dolutegravir Sodium,Lamivudine
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Fostemsavir is a small molecule drug, which is currently being evaluated in Phase III clinical studies for the treatment of hiv infections.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
February 06, 2026
Details:
Cabotegravir is a small molecule drug candidate, which is currently being evaluated in Phase I/ Phase II clinical studies for the treatment of HIV Infections.
Lead Product(s): Cabotegravir
Therapeutic Area: Infections and Infectious Diseases Brand Name: Undisclosed
Study Phase: Phase I/ Phase IIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable December 10, 2025
Lead Product(s) : Cabotegravir
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I/ Phase II
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
A Study to Investigate Cabotegravir for Neonates Exposed to HIV-1
Details : Cabotegravir is a small molecule drug candidate, which is currently being evaluated in Phase I/ Phase II clinical studies for the treatment of HIV Infections.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
December 10, 2025
Details:
VH4524184 is currently being evaluated in Phase II clinical studies for the treatment of HIV Infections.
Lead Product(s): VH4524184,Emtricitabine,Tenofovir Alafenamide
Therapeutic Area: Infections and Infectious Diseases Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Undisclosed
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable October 02, 2025
Lead Product(s) : VH4524184,Emtricitabine,Tenofovir Alafenamide
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
A Phase 2b Study Evaluating Oral VH4524184 Regimens in Treatment Naïve Persons With HIV-1 (INNOVA...
Details : VH4524184 is currently being evaluated in Phase II clinical studies for the treatment of HIV Infections.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
October 02, 2025
Details:
VH4524184 is a drug candidate, which is currently being evaluated in Phase I clinical studies for the treatment of HIV Infections.
Lead Product(s): VH4524184,Itraconazole,Rifabutin,Phenytoin,Metformin
Therapeutic Area: Infections and Infectious Diseases Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Undisclosed
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable July 15, 2025
Lead Product(s) : VH4524184,Itraconazole,Rifabutin,Phenytoin,Metformin
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Study of VH4524184 Tablet Absorption, Food Effect, & Drug Interaction in Healthy Adults
Details : VH4524184 is a drug candidate, which is currently being evaluated in Phase I clinical studies for the treatment of HIV Infections.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
July 15, 2025
Details:
VH3810109 is a Antibody drug candidate, which is currently being evaluated in Phase I clinical studies for the treatment of HIV Infections.
Lead Product(s): VH3810109,Fostemsavir
Therapeutic Area: Infections and Infectious Diseases Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Antibody, Unconjugated
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable July 08, 2025
Lead Product(s) : VH3810109,Fostemsavir
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
VH3810109 ± Fostemsavir Effect On HIV Viral Reservoir In PLWH
Details : VH3810109 is a Antibody drug candidate, which is currently being evaluated in Phase I clinical studies for the treatment of HIV Infections.
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Inapplicable
July 08, 2025
Details:
Cabotegravir is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of HIV Infections.
Lead Product(s): Cabotegravir,Lenacapavir
Therapeutic Area: Infections and Infectious Diseases Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable May 14, 2025
Lead Product(s) : Cabotegravir,Lenacapavir
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Cabotegravir is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of HIV Infections.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
May 14, 2025
Details:
VH109, a CD4-binding broadly neutralising antibody, in combination with monthly cabotegravir long-acting (CAB LA), successfully kept viral levels suppressed in adults living with HIV.
Lead Product(s): VH109,Cabotegravir
Therapeutic Area: Infections and Infectious Diseases Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Antibody, Unconjugated
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable March 12, 2025
Lead Product(s) : VH109,Cabotegravir
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
ViiV’s N6LS Antibody Maintains Long-Acting Viral Suppression in HIV Treatment
Details : VH109, a CD4-binding broadly neutralising antibody, in combination with monthly cabotegravir long-acting (CAB LA), successfully kept viral levels suppressed in adults living with HIV.
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Inapplicable
March 12, 2025
Details:
Cabotegravir is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of HIV Infections.
Lead Product(s): Cabotegravir
Therapeutic Area: Infections and Infectious Diseases Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable January 22, 2025
Lead Product(s) : Cabotegravir
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Cabotegravir is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of HIV Infections.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
January 22, 2025
Details:
Cabotegravir is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of HIV Infections.
Lead Product(s): Cabotegravir
Therapeutic Area: Infections and Infectious Diseases Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable December 19, 2024
Lead Product(s) : Cabotegravir
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Cabotegravir is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of HIV Infections.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
December 19, 2024
Details:
Vocabria (cabotegravir) is an HIV-1 integrase strand transfer inhibitor indicated in combnation with rilpivirine for adolescents' PrEP to reduce risk of sexually acquired HIV-1 infection.
Lead Product(s): Cabotegravir,Rilpivirine
Therapeutic Area: Infections and Infectious Diseases Brand Name: Vocabria
Study Phase: Approved FDFProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable December 16, 2024
Lead Product(s) : Cabotegravir,Rilpivirine
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
ViiV Healthcare Announces CHMP Positive Opinion for Vocabria + Rekambys HIV Treatment
Details : Vocabria (cabotegravir) is an HIV-1 integrase strand transfer inhibitor indicated in combnation with rilpivirine for adolescents' PrEP to reduce risk of sexually acquired HIV-1 infection.
Product Name : Vocabria
Product Type : Miscellaneous
Upfront Cash : Inapplicable
December 16, 2024
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]FDF Dossiers
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]FDA Orange Book
Europe
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Inspections and registrations
ABOUT THIS PAGE
Share 
